SPONSOR
Jiangsu HengRui Medicine Co., Ltd.
Total Trials
5
Recruiting
5
Phases
Phase 1, Phase 2, Phase 3
Conditions studied: Advanced Solid TumorsAbirritation in the ICUHER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant TherapyGastric CancerLung Cancer
NCT05473624 Phase 1
Recruiting
Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors
Advanced Solid Tumors
NCT07372924 Phase 2
Recruiting
A Trial of Tegileridine Fumarate Lnjection for Prolonged Mechanical Ventilation Abirritation in the Intensive Care Unit (ICU)
Abirritation in the ICU
NCT06126640 Phase 3
Recruiting
A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
NCT04342910 Phase 3
Recruiting
Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC
Gastric Cancer
NCT07241767 Phase 2
Recruiting
A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung Cancer
Lung Cancer